Literature DB >> 11231578

c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells.

R Gavioli1, T Frisan, S Vertuani, G W Bornkamm, M G Masucci.   

Abstract

Burkitt's lymphoma (BL) is a highly malignant B-cell tumour characterized by chromosomal translocations that constitutively activate the c-myc oncogene. Here we show that BL cells are resistant to apoptosis and do not accumulate ubiquitin conjugates in response to otherwise toxic doses of inhibitors of the proteasome. Deubiquitinating enzymes and the cytosolic subtilisin-like protease tripeptidylpeptidase II are upregulated in BLs, and could be rapidly induced by the overexpression of c-myc in normal B cells carrying oestrogen-driven recombinant Epstein-Barr virus. Apoptosis was induced by inhibiting tripeptidylpeptidase II, suggesting that the activity of this protease may be required for the survival of BL cells. We thus show that there is a regulatory link between c-myc activation and changes in proteolysis that may affect malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11231578     DOI: 10.1038/35060076

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  28 in total

1.  MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Authors:  Martin S Staege; Steven P Lee; Teresa Frisan; Josef Mautner; Siegfried Scholz; Alexander Pajic; Alan B Rickinson; Maria G Masucci; Axel Polack; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

2.  Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53.

Authors:  Deborah Stewart; Anirban Ghosh; Greg Matlashewski
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 3.  Reverse the curse--the role of deubiquitination in cell cycle control.

Authors:  Ling Song; Michael Rape
Journal:  Curr Opin Cell Biol       Date:  2008-03-17       Impact factor: 8.382

4.  Tripeptidyl Peptidase II Mediates Levels of Nuclear Phosphorylated ERK1 and ERK2.

Authors:  Anne Wiemhoefer; Anita Stargardt; Wouter A van der Linden; Maria C Renner; Ronald E van Kesteren; Jan Stap; Marcel A Raspe; Birgitta Tomkinson; Helmut W Kessels; Huib Ovaa; Herman S Overkleeft; Bogdan Florea; Eric A Reits
Journal:  Mol Cell Proteomics       Date:  2015-06-03       Impact factor: 5.911

5.  Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.

Authors:  Federica Destro; Fabio Sforza; Mariaconcetta Sicurella; Diego Marescotti; Eleonora Gallerani; Anna Baldisserotto; Mauro Marastoni; Riccardo Gavioli
Journal:  Immunology       Date:  2011-02-22       Impact factor: 7.397

Review 6.  The protein-interaction network with functional roles in tumorigenesis, neurodegeneration, and aging.

Authors:  Jarmila Nahálková
Journal:  Mol Cell Biochem       Date:  2016-10-03       Impact factor: 3.396

7.  Molecular architecture and assembly mechanism of Drosophila tripeptidyl peptidase II.

Authors:  Beate Rockel; Jürgen Peters; Shirley A Müller; Gönül Seyit; Philippe Ringler; Reiner Hegerl; Robert M Glaeser; Wolfgang Baumeister
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

Review 8.  Immune escape by Epstein-Barr virus associated malignancies.

Authors:  Christian Münz; Ann Moormann
Journal:  Semin Cancer Biol       Date:  2008-10-19       Impact factor: 15.707

9.  Multifarious proteomic signatures and regional heterogeneity in glioblastomas.

Authors:  Chul-Kee Park; Ji Hye Jung; Sung-Hye Park; Hee-Won Jung; Byung-Kyu Cho
Journal:  J Neurooncol       Date:  2009-02-15       Impact factor: 4.130

10.  Characterization of bortezomib-adapted I-45 mesothelioma cells.

Authors:  Lidong Zhang; James E Littlejohn; Yu Cui; Xiaobo Cao; Chander Peddaboina; W Roy Smythe
Journal:  Mol Cancer       Date:  2010-05-18       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.